Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251641 | 0.97 | SCNN1A (0.56) | SCNN1AKCNH2 | |
| SCHEMBL12251723 | 0.92 | SCNN1A (0.56) | SCNN1AKCNH2 | |
| SCHEMBL12251728 | 0.92 | SCNN1A (0.56) | SCNN1AKCNH2 | |
| SCHEMBL12251721 | 0.92 | SCNN1A (0.59) | SCNN1A | |
| SCHEMBL12251729 | 0.92 | SCNN1A (0.55) | SCNN1AKCNH2 | |
| SCHEMBL12433380 | 0.92 | SCNN1A (0.55) | SCNN1AKCNH2 | |
| SCHEMBL917014 | 0.91 | SCNN1A (0.60) | SCNN1A | |
| SCHEMBL12251645 | 0.90 | SCNN1A (0.53) | SCNN1AKCNH2 | |
| SCHEMBL12251634 | 0.90 | SCNN1A (0.53) | SCNN1AKCNH2 | |
| SCHEMBL2290200 | 0.90 | SCNN1A (0.53) | SCNN1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981898-B2 | Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes | PARION SCIENCES, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981898-B2 | Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes | PARION SCIENCES, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090082287-A1 | METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES | PARION SCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082287-A1 | METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES | PARION SCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2008031048-A2 | ENHANCED MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES | PARION SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082287-A1 | METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES | SCNN1B, SLC10A2, SCNN1A | SCNN1A 3/4885KCNH2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.